Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

10.85USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$10.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
334,489
52-wk High
$35.60
52-wk Low
$8.68

Chart for

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: 2.56
Market Cap(Mil.): $734.69
Shares Outstanding(Mil.): 67.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Alder Biopharmaceuticals Q2 loss per share $1.48

* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results

Aug 08 2017

BRIEF-Alder Biopharmaceuticals announces commencement of public offering of common stock

* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock

Jul 11 2017

Alder's shares tumble as migraine drug data disappoints

Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.

Jun 27 2017

UPDATE 4-Alder's shares tumble as migraine drug data disappoints

* Shares fall as much as 26 pct to 2 1/2 yr-low (Adds analyst comment, updates shares)

Jun 27 2017

BRIEF-Alder Biopharmaceuticals announces positive eptinezumab phase 3 results

* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

Jun 27 2017

Alder's migraine drug meets main goal in late-stage study

June 27 Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.

Jun 27 2017

BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine

* Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion

Apr 28 2017

BRIEF-Alder Biopharmaceuticals reports Q1 loss per share $2.00

* Alder Biopharmaceuticals announces first quarter 2017 financial and operating results

Apr 27 2017

BRIEF-Alder Biopharmaceuticals top-line results from promise 1 expected later this quarter

* Alder Biopharmaceuticals Inc - top-line results from promise 1 expected later this quarter Source text for Eikon: Further company coverage:

Apr 24 2017

Earnings vs. Estimates